Section
A novel thrombin-cleavable FVIII-mimetic antibody enables dynamic, on-demand control of coagulation, reducing adverse thrombotic risk while maintaining efficacy in hemophilia A treatment.
This article reviews how non-alpha IL2 receptor agonist pegenzileukin can counteract CD8 T-cell exhaustion, a key mechanism in CAR T-cell (CART19) therapy failure in relapsed/refractory large B-cell lymphoma, enhancing therapeutic efficacy
Rapid and excessive expansion of ciltacabtagene autoleucel (cilta-cel) CAR T-cells associates with delayed neurotoxicity in relapsed/refractory multiple myeloma, with absolute lymphocyte count serving as a practical biomarker to guide early
This prospective nationwide study identifies baseline peripheral blood UBA1 variant allele frequency as a robust predictor of poor outcomes in VEXAS syndrome, providing a new tool for risk stratification and management.
IL-6 receptor inhibition during hematopoietic stem cell transplantation fosters type I interferon responses and promotes expansion of cytolytic CD4+ T cells, including Eomes+ subsets, augmenting antitumor immunity while mitigating graft-ver
Review of recent studies highlights venetoclax plus azacitidine as a feasible and effective therapy in younger AML patients, challenging standard intensive chemotherapy paradigms and suggesting a shift toward lower-intensity regimens with c
A multicenter Chinese registry study demonstrates that direct oral anticoagulants are noninferior to warfarin in preventing 1-year symptomatic recurrent venous thromboembolism after cerebral venous thrombosis, with exploratory bleeding outc
Targeting the mitochondrial complex I subunit NDUFS2 enhances sensitivity to FLT3 inhibitors and overcomes drug resistance in acute myeloid leukemia with FLT3-ITD mutations, suggesting a promising therapeutic strategy.
The INTERVENE trial reveals that adding midostaurin to low-dose cytarabine and venetoclax is tolerable and improves FLT3-ITD clearance and survival in older AML patients with FLT3-ITD, addressing resistance in this high-risk subgroup.
A large nationwide cohort study reveals that patients with hematological malignancies and other immunosuppressive conditions have significantly higher risks of ICU-acquired infections, while those with solid tumors do not show increased inc
This study identifies immunoglobulin heavy chain constant domain-derived peptides as promising TCR therapy targets in multiple myeloma, demonstrating selective cytotoxicity and potential to preserve humoral immunity.
Early increases in serum ST2 and REG3α within the first week after haploidentical stem cell transplantation with post-transplant cyclophosphamide predict transplant outcomes, highlighting their potential as prognostic biomarkers.
This study evaluates how treatment for cholecystitis affects the timely resumption of cancer therapy, highlighting that half of cancer patients return to therapy within six weeks, with hematologic malignancies and drainage procedures linked
This article reviews how genetic profiling and dynamic laboratory markers predict clinical outcomes in advanced systemic mastocytosis treated with KIT inhibitors avapritinib and midostaurin, facilitating optimized treatment strategies.
This comprehensive analysis of 8,553 AML patients reveals diverse RAS mutation patterns, their associations with other genomic alterations, and distinct prognostic implications influenced by the genomic context and treatment modalities, gui
This phase 3 trial demonstrates that a chemotherapy-free regimen combining ponatinib and blinatumomab significantly improves event-free survival over imatinib plus chemotherapy in adults with Philadelphia chromosome-positive acute lymphobla
Two hemophilia A patients developed persistent high-titer FVIII inhibitors following AAV-mediated gene therapy with a bioengineered FVIII transgene despite prior extensive FVIII exposure.
Mitochondrial transfer from pediatric AML blasts to macrophages via tunneling nanotubes induces metabolic and immunosuppressive reprogramming, impairing anti-leukemic immune responses and supporting chemoresistance, revealing potential targ
This case series examines immunosuppressive management and long-term outcomes in nine Japanese patients undergoing single living-donor lobar lung transplantation from the same donor as prior HSCT, revealing viable reduced immunosuppression
PPM1D mutations and overexpression are involved in MPN pathogenesis, with dual PPM1D and HDM2 inhibition emerging as a promising therapeutic strategy, particularly for myelofibrosis patients.
